arrow
B

Byung Ik Jang

yeungnam university hospital
H指数:34
被引数:4,101

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations

东亚和西方人群中急性重度溃疡性结肠炎的不同预测因素

2026-06-050
OAAI
One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: an Asan-Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicenter real-world cohort study

奥马珠单抗治疗溃疡性结肠炎患者的一年有效性与安全性:一项大邱庆北克罗恩病与结肠炎协会(CCAiD)多中心真实世界队列研究

2026-01-010
PRE
Comparative efficacy of subcutaneous infliximab switching in remission and non-remission patients with inflammatory bowel disease after intravenous maintenance: 1-year outcome from a multicentre cohort study

静脉维持治疗后炎症性肠病患者的皮下英夫利昔单抗转换治疗比较疗效:一项多中心队列研究的一年结果

2025-04-230
OA
Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patients
2025-01-220
PRE
Uncontrolled clinical activity and anti-TNF plus thiopurine combination therapy are predictive factors of 1-year infection risk following acute severe ulcerative colitis: AOCC and ANZIBDC collaboration study
2025-01-220
PRE
Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study

东亚患者和医生对炎症性肠病补充和替代药物使用的观点: 一项横断面,跨国研究的结果

2022-04-303
OAAI
Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study
2022-03-249
OAAI
The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study

韩国溃疡性结肠炎患者维多珠单抗的真实世界结局: 一项多中心回顾性研究

2021-07-0512
OAAI
Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease

接受抗TNF治疗炎症性肠病的母亲所生婴儿接种卡介苗的安全性和最佳时机

2020-05-1722
PREAI
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study
2020-01-307
OAAI